WINNIPEG, MB–(Marketwired – November 14, 2016) – 3D Signatures Inc. (TSX VENTURE: DXD) (the “Company” or “3DS”) is pleased to introduce its Clinical and Scientific Advisory Board (CSAB), comprised of world-renowned physicians and researchers. The CSAB, made up of external experts, will serve as a resource to Dr. Sabine Mai, Director and Chair of 3DS’ Clinical and Scientific Advisory Board and 3DS’ CEO, Jason Flowerday. The CSAB will help guide the clinical development of 3DS’ proprietary genomic analysis software from research, right through to validation and regulatory approval. The Company is currently focused on Prostate Cancer, Hodgkin’s Lymphoma, Multiple Myeloma, and Alzheimer’s disease.
Sabine Mai, PhD
Dr. Sabine Mai is a tenured Professor of Physiology and Pathophysiology, Biochemistry and Medical Genetics, Human Anatomy and Cell Science, University of Manitoba. She is also Director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD) at University of Manitoba. Dr. Mai is an internationally known researcher who has more than one hundred publications related to research on Genomic Instability and the 3D nuclear organization in cancer and Alzheimer’s disease. Most recently she has contributed to a library of patents related to her work on 3D Genomic Analysis. She is the recipient of numerous academic awards including the Braidwood Jackson Memorial Award; the Dr. Saul Highman Memorial Award; the Rh Award (Basic Science); the J&J Cognition Challenge (2013). She was recognized in 2015 as one of the Top 100: Canada’s Most Powerful Women and has recently accepted an Editorial Board Member position with Genes, Chromosomes and Cancer, a high-profile peer-reviewed academic journal.
Kenneth C. Anderson, MD
Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School, as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at Johns Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in it is microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome.
Laurence Klotz, MD
Dr. Klotz is internationally recognized for his contributions to the treatment of prostate cancer, notably for pioneering the adoption of Active Surveillance as a standard aspect of patient care. Dr. Klotz obtained his medical degree and residency training from the University of Toronto with a special fellowship in uro-oncology and tumour biology at Memorial Sloan Kettering Cancer Centre, New York. He is a widely published uro-oncologist who serves on the board or heads many medical/scientific organizations. He is a Professor, Department of Surgery, University of Toronto, past Chief of Urology, Sunnybrook Health Sciences Centre, Toronto, and Chairman, World Uro-Oncology Federation. Dr. Klotz was awarded the Order of Canada in 2014 for his contribution to prostate cancer treatment.
Hans Knecht, MD
Dr. Knecht established himself as a prominent haematologist through his ground-breaking translational research on lymphoma biology. His current focus is on the molecular events leading to the transition from the mononuclear Hodgkin to the multinuclear Reed-Sternberg cell and the impact of 3D nuclear telomere organization on this transformation. Dr. Knecht received his medical degree from the University of Zurich, Switzerland with post-graduate work under both Maxime Seligmann (Haematology) and Karl Lennert (Haematopathology) in Paris and Kiel, respectively. Dr. Knecht is currently a Professor of Medicine and Chief, Division of Haematology at McGill University and Jewish General Hospital, Montreal.
Darrel Drachenberg, MD
Dr. Drachenberg is a urologic oncologist and researcher and strong proponent of Active Surveillance for prostate cancer patients. Dr. Drachenberg attended medical school at the University of British Columbia and urology residency at Dalhousie University. He is an American Foundation of Urology Scholar with fellowship training in urologic oncology at the National Cancer Institute in Bethesda, Maryland. He founded the laparoscopic urology program and prostate brachytherapy, cryotherapy, and HIFU programs at the University of Manitoba where he works as assistant professor of surgery and director of research for the Manitoba Prostate Center and Section of Urology and Chair of the Genito-Urinary disease site group, CancerCare Manitoba.
Rami Kotb, MD
Dr. Kotb completed his medical residency training in Paris, France, and then became a staff member at Paris XI University. He joined the Hematology-Oncology team at Sherbrooke University (QC, Canada) in 2005 as an Assistant, then Associate Professor. He also worked as the Director of Hematology undergraduate education, Head of the supra-regional team of Hematological Neoplasia and Head of the Institutional Oncology Quality Sub-committee. Late 2011, he moved to British Columbia to work at the BC Cancer Agency as an Oncologist/Hematologist, Associate Professor at the University of British Columbia and affiliate Professor at the University of Victoria. He joined the team at CancerCare Manitoba in September 2014. His practice and research activity will be focused on lymphoid neoplasia, primarily myeloma and lymphoma.
Thomas Cremer, MD
Dr. Cremer is an internationally-recognized scientist specializing in the study of nuclear architecture. He is one of the pioneers of interphase cytogenetics and comparative genomic hybridization (CGH). These methods have become widely used tools for cytogenetic analyses of chromosomal imbalances. He is a corresponding member of the Heidelberg Academy for Sciences and Humanities since 2000, a member of Germany’s National Academy of Sciences Leopoldina since 2006, and an honorary member of both the European Cytogenetics Association (ECA) and the German Society of Human Genetics since 2011, as well as the recipient of the medal of Honor of this Society. Dr. Cremer is an independent expert to 3DS.
Comments from Dr. Sabine Mai
“The newly formed CSAB will be invaluable in guiding our clinical programs,” said Dr. Sabine Mai, Company Director and Chair of 3DS’ Clinical and Scientific Advisory Board. “Each member is a distinguished leader in their field and can bring insights that will help us achieve our objectives: to validate and secure the approval of accurate and minimally invasive first-in-class biomarkers that allow clinicians to personalize treatments and improve outcomes for cancer and Alzheimer’s disease patients.”
3D Signatures Included in Major Clinical Trial for Prostate Cancer
The Company recently announced participation in a major clinical trial for prostate cancer diagnosis and management known as PRECISE (PRostate Evaluation for Clinically Important disease MRI vs Standard Evaluation procedures). The trial marks the Company’s first step toward validation and approval of clinical risk assessment tests for prostate cancer. It is currently being tested as a new blood-based biomarker to accurately stratify Prostate Cancer patients into risk groups. Such a tool does not currently exist for prostate cancer patients. For more information about the PRECISE Trial and Prostate Cancer Canada, please visit their website at http://www.prostatecancer.ca.
About 3DS
3DS (TSX VENTURE: DXD) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis chromosomal signatures. The technology is well developed and supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, the technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company’s new website at http://www.3dsignatures.com.
Forward-Looking Information
This news release includes forward-looking statements that are subject to risks and uncertainties. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. All statements within, other than statements of historical fact, are to be considered forward looking. In particular, the Company’s statements that it expects to benefit greatly from its association with the individuals named in this news release is forward-looking information. Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Risk factors that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other things: market demand; technological changes that could impact the Company’s existing products or the Company’s ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; the ability to manage operating expenses, which may adversely affect the Company’s financial condition; the Company’s ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of infringement of their intellectual property rights; adverse results or unexpected delays in clinical trials; changes in laws, general economic and business conditions; and changes in the regulatory regime. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Hugh Rogers
VP Corporate Finance
604-250-6162
[email protected]
